Deucrictibant is an investigational new drug that is being evaluated by Pharvaris for the treatment of hereditary angioedema (HAE). It is a bradykinin receptor B2 antagonist which blocks bradykinin-driven swelling attacks which is a characteristic of HAE.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.